Skip to main content
. Author manuscript; available in PMC: 2020 Sep 25.
Published in final edited form as: Invest New Drugs. 2019 Jun 6;37(4):755–762. doi: 10.1007/s10637-019-00797-1

Table 2.

Adverse events regardless of attribution (n = 29)

Adverse Event Grade
1 2 3 4
N % N % N % N %
Anemia 15 51.7 5 17.2 1 3.4
Abdominal pain 7 24.1 6 20.7 1 3.4
Hypokalemia 5 17.2 2 6.9 3 10.3
Diarrhea 8 27.6 1 3.4
Fatigue 3 10.3 4 13.8 1 3.4
Nausea 5 17.2 1 3.4 2 6.9
Alkaline phosphatase elevation 4 13.8 1 3.4 2 6.9
Aspartate aminotransferase elevation 4 13.8 1 3.4 1 3.4
Cardiac troponin elevation 3 10.3 2 6.9 1 3.4
Hypercalcemia 5 17.2
Vomiting 2 6.9 3 10.3
Hyperphosphatemia 1 3.4 3 10.3
Abdominal distension 2 6.9 1 3.4
Alanine aminotransferase elevation 1 3.4 1 3.4 1 3.4
Hypertension 3 10.3
Hyponatremia 1 3.4 2 6.9
Hyperbilirubinemia 1 3.4 1 3.4
Hyperglycemia 2 6.9
Dehydration 2 6.9
Dry skin 2 6.9
Dyspepsia 2 6.9
Dyspnea 1 3.4 1 3.4
Edema limbs 1 3.4 1 3.4
Leukopenia 2 6.9
Muscle weakness 2 6.9
Neutropenia 1 3.4 1 3.4
Pain in extremity 1 3.4 1 3.4
Hypoalbuminemia 1 3.4 1 3.4
Hyperkalemia 1 3.4 1 3.4
Adrenal insufficiency 1 3.4
Anorexia 1 3.4
Arrhythmia 4 13.8 1 3.4
Back pain 1 3.4
Cardiac troponin I elevation 1 3.4
Chills 1 3.4
Constipation 1 3.4
Fever 1 3.4
Flushing 1 3.4
Gastritis 1 3.4
Hand-and-foot syndrome/reaction 1 3.4
Insomnia 1 3.4
Lymphopenia 1 3.4
Oral mucositis 1 3.4
Myalgia 1 3.4
Palpitations 1 3.4
Pericardial effusion 1 3.4
Thrombocytopenia 1 3.4
Hypocalcemia 1 3.4
Skin hyperpigmentation 1 3.4
Taste alteration 1 3.4
Urinary tract infection 1 3.4